请使用支持JavaScript的浏览器!
主营:分子类,蛋白类,抗体类,生化类试剂
℡ 4000-520-616
℡ 4000-520-616
axonmedchem/AVE 0118 hydrochloride/5 mg/Axon 2243
产品编号:Axon2243
市  场 价:¥2400.00
场      地:美国(厂家直采)
产品分类: 蛋白类>聚合物>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$120.00
品      牌: axonmedchem
公      司:axonmedchem
公司分类:
axonmedchem/AVE 0118 hydrochloride/5 mg/Axon 2243
商品介绍

AVE 0118 hydrochloride

Based on 8 reference(s) in Google Scholar9108

Axon 2243

CAS [498577-53-0 (parent)]

MF C30H29N3O3.HClMW 516.03

  • Purity:99%
  • Soluble in water and DMSO

AVE 0118 hydrochloride

Description

Potassium channel blocker. AVE0118 caused concentration-dependent inhibition of Kv1.5 (IKur), Kv4.3 (Ito),Kir3.4 (IKAch), and IKr currents (IC50 values 6.2 μM,3.4 μM, 4.5 μM, and 10 μM resp.). A potent and atrium selective antiarrhythmic compound with no apparent effect on ventricular repolarization. Noteworthy, the atrial selective and dose-dependent prolongation of atrial refractoriness (ERP) by AVE 0118 has been claimed to be an inhibitory effect of sodium channel activity in an atrial-selective manner, and may therefor contribute to anti-AF properties of AVE0118.
H. Gögelein et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naun. Schmiedebergs Arch. Pharmacol. 2004, 370, 183-192.
K.J. Wirth et al. Atrial effects of the novel K+-channel-blocker AVE0118 in anesthetized pigs. Cardiovascular Res. 2003, 60, 298-306.
A. Burashnikov et al. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J. Cardiovasc. Pharmacol. 2012, 59, 539-546.
  • Certificate of Analysis
  • Material Safety Data Sheet
CardiovascularCell Signaling & OncologyCNSDiabetes & MetabolismPain & InflammationKv1.5Kv4.3Kir4.3KCND3KCNJ5KCNE1
Potassium channel blocker (Kv1.5 (IKur), Kv4.3 (Ito),Kir3.4 (IKAch), and IKr currents)

Chemical name

2"-((2-(4-methoxyphenyl)acetamido)methyl)-N-(2-(pyridin-3-yl)ethyl)biphenyl-2-carboxamide hydrochloride

Parent CAS No.

[498577-53-0]

品牌介绍

Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。

自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔